

RECOMMENDATIONS

Rating	BUY ▲
Risk	High
Price Target	\$0.07
Share Price	\$0.02


SNAPSHOT

Monthly Turnover	\$1.8mn
Market Cap	\$17mn
Shares Issued	735.6mn
52-Week High	\$0.05
52-Week Low	\$0.02
Sector	Health Care

BUSINESS DESCRIPTION

Cellmid is an early stage biotech company being built around midkine, a protein known to contribute to various diseases including cancer, heart disease and inflammation. Cellmid intends to go to the clinic in the first half of 2015 with an anti-midkine antibody in cancer and has a number of licensing agreements with diagnostics developers on the use of midkine as a cancer diagnostic. Cellmid also owns a small but growing business selling hair restoration products.

12-MONTH PRICE & VOLUME



RESEARCH ANALYST

Stuart Roberts
+612 9250 8913
sroberts@baillieuholst.com.au

Disclosure

The author owns no shares in CDY.

Cellmid (CDY)

INITIATION OF COVERAGE

It's rare for one company to own a whole new target this big

- Company description.** Cellmid is an early stage biotech company built around midkine, a protein known to contribute to various diseases including cancer, heart disease and inflammation. Cellmid intends to go to the clinic in the first half of 2015 with an anti-midkine antibody in cancer and has a number of licensing agreements with developers regarding the use of midkine as a cancer diagnostic. Cellmid also owns a small but growing business selling hair restoration products.
- It's rare for one company to own a whole new target this big.** Ordinarily, biotech companies differentiate themselves through the kind of drugs they have developed against targets that have been validated by others. By contrast, investors in Cellmid effectively control, through a comprehensive patent portfolio, a new target in midkine that is relevant across a wide range of diseases including heart disease and kidney disease, as well as cancer.
- Cellmid intends to go to the clinic in the first half of 2015 with an anti-midkine antibody in cancer.** Given midkine's multiple roles in cancer progression across a range of tumours we see strong upside for this programme, especially since there is so much demand for new cancer antibodies from Big Pharma. Cellmid expects to read out data next year from its first Phase I/II study in cancer patients.
- Cellmid is a player in personalised cancer medicine.** Cancer treatment is increasingly becoming 'personalised', meaning that drugs are being developed specific for subgroups within a patient population and administered depending on whether or not the patient expresses particular biomarkers. We expect midkine to be such a biomarker, which means that Cellmid already has the companion diagnostic for a future therapy. This ability to personalise its therapies will make it easier for the company to do business with Big Pharma.
- Cellmid has various early stage revenue opportunities,** including three licensees for midkine diagnostics, and the hair regrowth business. We like the way in which CEO, Maria Halasz and her team have created these opportunities without neglecting the medium and long term opportunities from midkine.
- Cellmid is undervalued on our numbers.** We value Cellmid at \$0.07 base case and \$0.26 optimistic case using a probability-weighted DCF approach. Our target price of \$0.07 sits at our base case.

INVESTMENT SUMMARY

Year End: 30 June		2012 (A)	2013 (A)	2014 (E)	2015 (E)	2016 (E)
Revenue	\$mn	0	1	2	13	23
EBITDA	\$mn	-2.7	-2.3	-2.1	1.2	10.4
EBIT	\$mn	-2.7	-2.4	-2.1	1.2	10.4
Reported Profit	\$mn	-2.0	-1.5	-1.4	1.3	10.6
Adjusted Profit	\$mn	-2.0	-1.5	-1.4	1.3	10.6
EPS (Reported)	¢	-0.4	-0.2	-0.1	0.1	0.9
EPS (Adjusted)	¢	-0.4	-0.2	-0.1	0.1	0.9
EPS Growth	%	N/A	N/A	N/A	N/A	N/A
PER (Reported)	x	N/A	N/A	N/A	20.6	2.5
PER (Adjusted)	x	N/A	N/A	N/A	20.6	2.5
Dividend	¢	0.0	0.0	0.0	0.0	0.0
Yield	%	0.0	0.0	0.0	0.0	0.0
Franking	%	0	0	0	0	0

Financial summary

Code CDY
Analyst Stuart Roberts
Date 30 May, 2014
Share price \$0.02
Market capitalisation \$17m
Year end 30 June

Rating BUY
Price target \$0.07
Upside/downside 204.3%
Valuation \$0.07 / \$0.26
Valuation method Probability-weighted DCF
Risk High

PROFIT AND LOSS (A\$m)					
Y/e June 30 (A\$m)	FY12A	FY13A	FY14E	FY15E	FY16E
Revenue	0	1	2	13	23
EBITDA	-3	-2	-2	1	10
D&A	0	0	0	0	0
EBIT	-3	-2	-2	1	10
Net interest	0	0	0	0	0
Pre-tax profit	-3	-2	-2	1	11
Tax	1	1	1	0	0
NPAT	-2	-2	-1	1	11
Minority interests	0	0	0	0	0
Net profit after minorities	-2	-2	-1	1	11

BALANCE SHEET (A\$m)					
Y/e June 30	FY12A	FY13A	FY14E	FY15E	FY16E
Cash	1	2	3	7	17
Current receivables	0	0	0	1	1
Inventories	1	2	2	2	2
Other current assets	0	0	0	0	0
Current assets	2	4	5	9	21
PPE	0	0	0	0	0
Intangible assets	0	2	2	2	2
Other non-current assets	0	0	0	0	0
Non-current assets	0	2	2	2	2
Total assets	3	6	7	12	23
Payables	0	1	0	1	1
Debt	0	0	0	0	0
Other liabilities	0	0	0	0	0
Total liabilities	0	1	1	1	1
Shareholders' equity	2	5	6	11	22
Minorities	0	0	0	0	0
Total shareholders funds	2	5	6	11	22
Total funds employed	3	6	7	12	23
W/A shares on issue	427	564	735	835	835

CASH FLOW (A\$m)					
Y/e June 30	FY12A	FY13A	FY14E	FY15E	FY16E
NPAT plus discontinued ops.	-2	-2	-1	1	11
Non-cash items	0	0	0	0	0
Working capital	0	0	-1	-1	0
Other operating cash flow	0	0	0	0	0
Operating cashflow	-2	-1	-2	1	11
Capex	0	0	0	0	0
Investments	0	0	0	0	0
Other investing cash flow	0	-1	1	0	0
Investing cashflow	0	-1	1	0	0
Change in borrowings	0	0	0	0	0
Equity raised	1	3	2	3	0
Dividends paid	0	0	0	0	0
Other financing cash flow	0	0	0	0	0
Financing cashflow	1	3	2	3	0
Net change in cash	-1	1	1	4	11
Cash at end of period	1	2	3	7	17

EARNINGS (A\$m)					
Y/e June 30	FY12A	FY13A	FY14E	FY15E	FY16E
Net profit (\$m)	-2.0	-1.5	-1.4	1.3	10.6
EPS (c)	-0.5	-0.3	-0.2	0.2	1.3
EPS growth (%)	N/A	N/A	N/A	N/A	729%
P/E ratio (x)	-5.0	-8.4	-12.5	15.0	1.8
CFPS (c)	-0.4	-0.3	-0.3	0.1	1.3
Price/CF (x)	-5.6	-8.9	-8.5	20.0	1.8
DPS (c)	0.0	0.0	0.0	0.0	0.0
Yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Franking (%)	N/A	N/A	N/A	N/A	N/A
EV/EBITDA	-5.0	-5.8	-6.6	11.1	1.3
EV/EBIT	-5.0	-5.7	-6.4	11.2	1.3

PROFITABILITY RATIOS					
Y/e June 30	FY12A	FY13A	FY14E	FY15E	FY16E
EBITDA/revenue (%)	-2017.2%	-431.9%	-124.0%	9.0%	44.7%
EBIT/revenue (%)	-2025.4%	-435.1%	-128.0%	9.0%	44.7%
Return on assets (%)	-78.3%	-25.7%	-19.9%	11.0%	46.6%
Return on equity (%)	-94.4%	-29.0%	-21.9%	12.0%	49.0%
Return on funds empl'd (%)	-94.4%	-29.0%	-21.9%	12.0%	49.0%
Dividend cover (x)	N/A	N/A	N/A	0%	0%
Effective tax rate (%)	27.2%	33.8%	34.4%	0.0%	0.0%

LIQUIDITY AND LEVERAGE RATIOS					
Y/e June 30	FY12A	FY13A	FY14E	FY15E	FY16E
Net debt/(cash) (\$m)	-1	-2	-3	-7	-17
Net debt/equity (%)	-50.3%	-33.1%	-44.7%	-61.6%	-79.3%
Net interest cover (x)	N/A	N/A	N/A	N/A	N/A
Current ratio (x)	6.2	5.9	7.7	10.1	18.3

INTERIMS					
Y/e June 30 (\$m)	1H13A	2H13A	1H14A	2H14F	1H15F
Revenue	0	0	1	0	5
EBITDA	-1	-1	0	-2	-1
D&A	0	0	0	0	0
EBIT	-1	-1	-1	-2	-1
Net interest	0	0	0	0	0
Pre-tax profit	-1	-1	-1	-2	-1
Tax	1	0	1	0	0
NPAT	0	-1	0	-2	-1
Minority interests	0	0	0	0	0
Net profit after minorities	0	-1	0	-2	-1

VALUATION		
	Base	Optim.
Cancer therapeutic (A\$m)	45.6	202.1
Cancer diagnostic (A\$m)	14.2	52.3
Consumer Health (A\$m)	10.3	46.8
Value of Cellmid technology	70.0	301.2
Value of tax losses	6.6	6.6
Underlying R&D cost	-9.6	-9.6
Cash now (A\$m)	3.4	3.4
Cash from options and cash to be raised	14.4	14.4
Total value (A\$m)	84.8	315.9
Total diluted shares (million)	1212.9	1212.9
Value per share	\$0.07	\$0.26
Valuation midpoint	\$0.17	
Share price now (A\$ per share)	\$0.023	
Upside to midpoint	618.1%	

Introducing Cellmid (ASX: CDY)

- **Cellmid is building itself around midkine.** Midkine is a protein known to contribute to cancer, heart disease and inflammation. Cellmid intends to go to the clinic in the first half of 2015 with an anti-midkine antibody in cancer, and the company already has a number of licensing agreements with diagnostics developers on its use as a cancer diagnostic. Cellmid also owns a small but growing business selling hair restoration products.
- **Midkine is useful across a range of disease indications.** Midkine, often called simple 'mk' in the literature, is a small heparin-binding growth factor protein¹ that is important in embryonic development, and while almost undetectable in healthy adults, is highly expressed in cancer and autoimmune disorders. Significant elements of midkine include:
 - Its role in preventing apoptosis as well as in cell migration, angiogenesis and cell growth, which means that it works at various levels of cancer progression;
 - Its ability to up-regulate at the onset of inflammation, making it an ideal 'upstream' target in diseases such as diabetic nephropathy; and
 - Its involvement in the preservation and repair of injured tissue, suggesting a potential treatment for myocardial infarction.
- **Cellmid has positioned itself to dominate midkine.** Midkine was discovered in 1988 at Nagoya University by Professors Takashi Muramatsu and Kenji Kadomatsu². Up until now midkine has not generally been referred to as a 'hot' new disease target, but the number of published papers in the field each year has grown steadily. Cellmid in effect positioned itself as the world leader in midkine research when it acquired privately-held, Cell Signals in 2008 for US\$1.5m plus 20 million shares. The acquisition gave Cellmid a library of around 120 anti-midkine antibodies and a comprehensive patent portfolio protecting midkine and midkine antagonists globally.
- **Cellmid intends to go to the clinic in the first half of next year with an anti-midkine antibody in cancer.** Cellmid is currently pre-clinical with an antibody it believes will work particularly well in gastrointestinal and thoracic cancer. Given midkine's multiple role in cancer progression, the substantial published studies on human midkine expression in cancer patients, and the large body of animal studies to back it up, we see strong upside for this programme given the continued demand for new cancer antibodies from Big Pharma.
- **Cellmid has developed a suite of midkine diagnostics.** On evidence that midkine can be used to diagnose cancer at an early stage, Cellmid has been able to secure three licensees for midkine diagnostics. The first of these, a bladder cancer diagnostic developed by the New Zealand biotech Pacific Edge under license from Cellmid, was launched in the US in mid-2013. Cellmid will earn near-term revenue from Pacific Edge as well as from America's Quest Diagnostics, which has developed a lung cancer diagnostic; and from Japan's Fujikara, which is developing a diagnostic for early stage cancer.
- **Cellmid sees potential for midkine antagonists in inflammation,** with the company particularly focused on acute kidney injury and chronic kidney disease, as well as the prevention of surgical adhesions.
- **Midkine may prove useful in heart disease,** with evidence that midkine can help to shrink the size of a myocardial infarct and also prevent cardiac remodelling following the infarct. Given the continuing high incidence of AMI and heart failure we see strong partnering interest emerging for midkine in these indications.
- **Cellmid also owns a hair regrowth business.** In 2013 Cellmid acquired the global rights to évolis, a clinically validated hair regrowth product that works through inhibition of FGF-5. Cellmid had previously licensed the rights to Australia for this product in 2010. With no major hair regrowth product having been launched globally since the 1980s we see strong upside for the évolis range given the high level of hair loss in both sexes and the science that lies behind Cellmid's product. At the moment the business is small but Cellmid is building up its roster of global distribution partners for évolis.

Midkine is a relevant target
target in cancer, heart
disease and inflammation

¹ By small we mean only 13 kilodaltons or 121 amino acids in size. There are two midkine domains, called 'C' and 'N', with C traditionally regarded as the more interesting target although N is now emerging in importance (see Biochem J. 2013 May 1;451(3):407-15). Midkine has >90% amino acid identity between mammalian species (see Biochem Biophys Res Commun. 1991 Apr 30;176(2):792-7).

² Biochem Biophys Res Commun. 1988 Mar 30;151(3):1312-8.

Cellmid controls a new cancer target

- **Midkine is an ideal cancer target.** A protein is a particularly good cancer target if it is a) expressed in many different kinds of tumours, b) not present in healthy people, and c) if it can be found to play a role in cancer at various stages. Midkine is ideal in this regard because:
 - The protein is expressed highly in various malignant tumours – Cellmid estimates at least 26 types³ - but is almost absent in healthy people⁴;
 - The protein inhibits apoptosis⁵;
 - The protein promotes proliferation and migration in cancer⁶; and
 - The protein is involved in cancer angiogenesis⁷;
- **We know from the literature that midkine antagonists work in cancer.** Consider just three papers:
 - Takei et. al: showed in 2001 that antisense oligonucleotides to midkine were highly effective at suppressing tumour growth in a mouse model of rectal carcinoma⁸;
 - Sueyoshi et. al: showed in 2011 that midkine antibodies inhibited primary tumour growth and slowed metastasis in a xenograft model of osteosarcoma⁹; and
 - Kishida et. al. showed in 2012 that a midkine aptamer strongly suppressed neuroblastoma tumour growth in a mouse xenograft model¹⁰.
- **So how come there are no anti-midkine drugs in the clinic yet?** Midkine was first discovered in 1988, however up until now no drug development company has pursued its cancer therapeutic possibilities. We see three reasons for this:
 - Much of our knowledge about midkine has only emerged in the last five years;
 - Until recently most research interest in midkine had been in Japan, making it harder for the target to get noticed; and
 - Comprehensive control of the relevant intellectual property by Cellmid or its predecessor company Cell Signals, which Cellmid acquired in 2008, inhibited other groups from entering the field¹¹.
- **Cellmid will be in the clinic with a midkine antibody in cancer from the first half of 2015.** The company started humanising midkine monoclonal antibodies from its library in 2011 and by May 2014 had selected a lead candidate called CAB102 to take to the clinic. This candidate, in xenograft studies, shrunk non-small cell lung cancer tumours by 50% over 21 days in conjunction with carboplatin (p<0.01 versus carboplatin only). Cellmid intends to start a 12-patient open label dose-escalation study of CAB102 in multiple solid tumours from the first half of 2015, recruiting colorectal, lung and gastric cancer patients. The trial would likely yield interim data in mid-to-late 2015.
- **Cellmid is an emerging cancer antibody play.** Antibodies make great cancer drugs because of their exquisite specificity, low side effects and their synergies with existing chemotherapies. This has caused cancer antibodies to grow into a large drug class featuring blockbusters such as Roche's Rituxan¹² (US\$7.5bn in net sales in 2013), Avastin¹³ (US\$6.7bn) and Herceptin¹⁴ (US\$6.6bn). As a consequence of this success, Big Pharma is very comfortable with having many cancer antibodies in its pipeline. We therefore see potential for a licensing deal in the cancer spaces once the data comes in from the initial study.
- **Cellmid thinks it can develop a good 'trisppecific' antibody.** In April 2014 Cellmid announced that it had retained the Lisbon-based Biotechnol, an antibody developer¹⁵, to develop 'Tribodies' that could target midkine as well as additional oncogenic proteins like

Cellmid will have interim data from its first anti-midkine cancer trial next year

³ See the company's 31 March 2014 presentation, slide 16.

⁴ See Br J Pharmacol. 2014 Jun;171(12):2925-39. Epub 2014 Jan 27. This paper is authored by Darren Jones, Cellmid's Head of Product Development.

⁵ See PLoS One. 2013 Aug 16;8(8):e71093.

⁶ See Mol Cancer Res. 2014 May;12(5):670-80. Epub 2014 Feb 24.

⁷ See Cancer Res. 1997 May 1;57(9):1814-9.

⁸ Cancer Res. 2001 Dec 1;61(23):8486-91.

⁹ See Cancer Lett. 2012 Mar;316(1):23-30. Epub 2011 Oct 20.

¹⁰ See Cancer Res. 2013 Feb 15;73(4):1318-27. Epub 2012 Dec 14.

¹¹ It's worth noting that Amgen has paid attention in recent years - see Neoplasia. Apr 2008; 10(4): 340-346.

¹² Generic name rituximab, see www.rituxan.com. Rituxan gained FDA approval in November 1997.

¹³ Generic name bevacizumab, see www.avastin.com. Avastin gained FDA approval in February 2004.

¹⁴ Generic name trastuzumab, see www.herceptin.com. Herceptin gained FDA approval in September 1998.

¹⁵ Private held, www.biotechnolgroup.com.

checkpoint inhibitors¹⁶. Given the rising popularity of antibodies that have the ability to hit more than one target – Amgen bought Micromet for US\$1.16bn in early 2012 in order to lead the bispecific cancer antibody space – we see strong potential for this programme¹⁷.

- **Cellmid is a player in personalised cancer medicine.** Increasingly cancer treatment is becoming ‘personalised’, meaning that drugs are being developed specific for subgroups within a patient population and administered depending on whether or not the patient expresses particular biomarkers. Cellmid’s anti-midkine antibody is in our view likely to be a future personalised cancer medicine, prescribed only to patients having elevated midkine, as determined by a midkine diagnostic which the company has already invented.
- **The era of personalised cancer medicine is here, and is big business, as the record of Herceptin has amply showed.** Herceptin, as we noted above, was in 2013 a US\$6.6bn best-seller for Roche, but it only works for Her2-positive breast cancer, which is around 20% of all breast cancer. Other personalised cancer drugs have followed in Herceptin’s wake:
 - Roche’s Tarceva¹⁸, AstraZeneca’s Iressa¹⁹ and Boehringer Ingelheim’s Gilotrif²⁰ only work in NSCLC patients who have tumours with EGFR mutations, which is around 10-15% of all patients. Tarceva was a US\$1.4bn drug in 2013 and Iressa had US\$647m in 2013 sales;
 - Roche’s Zelboraf²¹ and GSK’s Tafinlar²² for metastatic melanoma only work in patients that have the BRAF V600E mutation in their tumour, which is 40-50% of malignant melanoma;
 - GSK’s Mekinist²³, also for metastatic melanoma is approved in patients that have both BRAF V600E and BRAF V600K mutations; and
 - Pfizer’s Xalkori²⁴ for non-small-cell lung cancer (LSCLC), only works for patients whose tumours carry the EML4-ALK fusion gene. That’s a mere 3-7% of all NSCLC.
- **Having a biomarker and a companion diagnostic today makes it easier for Cellmid to attract investors and do business with Big Pharma.** The trouble with personalised cancer medicine, from the perspective of an early stage company, is that generally the early clinical studies of a drug are the ones which define what biomarkers are appropriate, after which the clinical studies can be enriched for patients expressing the biomarkers. The rise of adaptive design in cancer studies makes this relatively easy from a regulatory standpoint, but it still often means a study in which the drug fails from an ‘all comers’ perspective but works for the patients that have the biomarkers²⁵. Investors don’t tend to like this, and Big Pharma has reason to be cautious until the first biomarker-enriched cohort studies yield data. Given that Cellmid already has both the biomarker and a diagnostic for it, the company has a strong advantage over other would-be personalised cancer drug developers.

Herceptin is a US\$6.6bn pa personalised cancer medicine

¹⁶ The ‘checkpoints’, a relatively new group of cancer targets, are protein kinases controlling the cellular response to DNA damage. Checkpoint inhibitors are therefore potentially useful in potentiating chemotherapy drugs that work by damaging the DNA of cancer cells.

¹⁷ Other companies involved in bispecific antibodies include Genmab, Immunomedics and Xencor.

¹⁸ Generic name erlotinib, see www.tarceva.com. Tarceva gained FDA approval in November 2004.

¹⁹ Generic name gefitinib, see www.iressa.com. Iressa gained FDA approval in May 2003.

²⁰ Generic name afatinib, www.gilotrif.com. Gilotrif gained FDA approval in July 2013.

²¹ Generic name vemurafenib, see www.zelboraf.com. Zelboraf gained FDA approval in August 2011.

²² Generic name dabrafenib, see www.tafinlar.com. Tafinlar gained FDA approval in May 2013.

²³ Generic name trametinib, see www.trametinib.com. Like Tafinlar, Mekinist also received FDA approval in May 2013.

²⁴ Generic name crizotinib, see www.xalkori.com. Xalkori gained FDA approval in August 2011.

²⁵ For a good example, see the 26 November 2013 release from Merrimack Pharmaceuticals (Cambridge, Ma., Nasdaq: MACK, www.merrimackpharma.com). Headlined ‘Merrimack Pharmaceuticals’ MM-121 Demonstrates Positive Signal in Two Phase 2 ER/PR+ Breast Cancer Studies’. Basically this study saw MM-121 miss its primary endpoint but look encouraging in terms of two biomarkers.

Cellmid also controls a new inflammation target

- There is a large body of work showing midkine to be a driver of inflammation and that antagonists of midkine are anti-inflammatory. Consider three prominent examples from the literature²⁶:
 - **Rheumatoid Arthritis.** In 2004 Maruyama showed, in a mouse model of RA, that midkine knockout mice seldom developed RA, while most of the wild-type mice did²⁷;
 - **Multiple Sclerosis.** In 2008 Wang et. al. were able to show that anti-midkine aptamers could alleviate experimental autoimmune encephalomyelitis – the standard animal model for MS – by expanding the regulatory T cell population²⁸; and
 - **Kidney inflammation.** In 2005 Sato et al. showed that kidney inflammation and damage were suppressed when mice were given anti-midkine oligos.²⁹
- **There are three inflammatory indications that Cellmid are going after in midkine,** namely kidney (for both acute kidney injury and chronic kidney disease), lung (as a potential COPD treatment) and surgical adhesion.

Cellmid may have the Next Big Thing in kidney disease

- **There is ample pre-clinical evidence that midkine antagonists would work in kidney disease:**
 - In 2001 Sato et al. showed that midkine facilitated neutrophil infiltration in ischemic renal injury³⁰
 - In 2006 and 2007 by Kosugi et. al. showed that midkine is a key driver in the pathogenesis of diabetic nephropathy³¹;
 - In 2011 Kato et. al. showed that midkine-driven neutrophil infiltration was involved in the protein overload model of acute kidney injury³²
- **The markets for kidney disease are large, growing and underserved:**
 - There are perhaps 800,000 acute kidney injuries in the US annually that require renal replacement therapy³³;
 - 11% of the US adult population or 26 million people have chronic kidney disease³⁴, driven by the rapid rise of diabetes prevalence; and
 - There are no on-market specific therapies, beyond steroids.
- **Cellmid has various renal indications in mind for midkine antibodies, including:**
 - preservation of kidney function in an environment of multi-organ failure, something that happens during sepsis. One study has suggested that up to 25% of hospitalised patients in the US experience acute kidney failure³⁵;
 - chemotherapy-related nephrotoxicity, which can be a serious issue with some cancer treatments, affecting for example, 5-10% of patients on the chemotherapy drug cisplatin³⁶;
 - diabetic nephropathy, a problem for around a third of all diabetics³⁷; and
 - glomerular sclerosis, which could allow Cellmid to gain Orphan Drug status - in the US perhaps 70,000 people have the most common type of this condition, called Focal Segmental Glomerulosclerosis³⁸.

Around 11% of the US adult population has chronic kidney disease

²⁶ There are many others. Consider, for example, the work of Narita et. al., who in 2008 showed that midkine is expressed by infiltrating macrophages in int-stent restenosis, making midkine antibodies potentially very valuable in preventing such restenosis. See J Vasc Surg. 2008 Jun;47(6):1322-9. Epub 2008 Mar 19.

²⁷ See Arthritis Rheum. 2004 May;50(5):1420-9.

²⁸ See Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3915-20. Epub 2008 Mar 4.

²⁹ See Kidney Int. 2005 Apr;67(4):1330-9.

³⁰ See J Immunol. 2001 Sep 15;167(6):3463-9.

³¹ See Lab Invest. 2007 Sep;87(9):903-13. Epub 2007 Jul 2.

³² See Clin Exp Nephrol. 2011 Jun;15(3):346-54. Epub 2011 Mar 1.

³³ Estimated from Crit Care Med. 2008 Apr;36(4 Suppl):S146-51.

³⁴ Source: NHANES data, see Am J Kidney Dis. 2003 Jan;41(1):1-12.

³⁵ See Ann Pharmacother. 2002 Jul-Aug;36(7-8):1261-7.

³⁶ See World J Gastroenterol. Aug 14, 2011; 17(30): 3510–3517.

³⁷ Consider that ~20-30% of previously diagnosed diabetics have microalbuminuria (see Am J Kidney Dis. 2002 Mar;39(3):445-59), the earliest stage of nephropathy. Around 5% will have macroalbuminuria and 0.8% elevated plasma creatinine, where the kidney is failing and the annualised risk of death is ~20% (see Kidney Int. 2003 Jan;63(1):225-32).

There are many other indications that Cellmid can go after in inflammation.

- Cellmid is focused on getting its first cancer indications underway before it focuses on inflammation. That said, there are two other areas beyond kidney disease where the company thinks it can make a difference:
 - **COPD.** Recent work has shown the feedback loop that exists between the lung and the kidney³⁹ (which Hobo et. al. have shown⁴⁰) is mediated by an enzyme called ACE, a cause of hypertension. Midkine is therefore potentially useful in treating lung damage driven by kidney damage, which would be useful in COPD patients with kidney disease. One study has suggested that 5-10% of COPD patients have undiagnosed renal failure⁴¹; and
 - **Surgical adhesion.** Abdominal adhesions are bands of fibrous tissue that can form between abdominal tissues and organs, causing them to stick together. Often this is caused by inflammation related to surgery. Inoh et. al. have shown that midkine plays a key role in these adhesions, so that anti-midkine antibodies could assist in their prevention⁴². Around half of all abdominal surgery typically features adhesions⁴³, which is significant given that there are more than a million abdominal procedures in the US each year⁴⁴.

Midkine is useful in heart attack and heart failure

- **Midkine can treat heart attacks and prevent heart failure.** Midkine is well-known as a facilitator of plaque formation after heart/vascular surgery. There is ample evidence that midkine with reparative activity forms after a myocardial infarction⁴⁵. Cellmid has pre-clinical evidence, from pig and mouse models, that midkine can reduce the damage from myocardial and cerebral infarct by preventing apoptosis and increases blood vessel formation:
 - Horiba et. al showed in 2006 that a midkine injection in midkine knockout mice could significantly reduced infarct size⁴⁶;
 - Fujkui et al. showed that even delayed administration of midkine could still attenuate cardiac remodelling after myocardial infarction⁴⁷; and
 - Ishiguro et. al showed in 2011 that intracoronary injection of midkine could cut ischemia/reperfusion injury in pigs⁴⁸.
- **There are a lot of heart attacks and heart failure out there.** In the US there will be around 720,000 heart attacks this year for people over 35⁴⁹, while around 5.1 million people, or ~2% of the population over 20, will enter heart failure⁵⁰.
- **A proof of concept study for heart attack was completed in April 2011.** Cellmid has done various pre-clinical studies in AMI and, as with inflammation, we expect that the midkine programme will move forward once Cellmid has some momentum in the use of midkine in cancer.

Midkine can repair the damage from a heart attack

³⁸ This was the disease which stunted the growth of the American actor Gary Coleman (1968-2010), famous for playing Arnold in the 1980s situation comedy *Diff'rent Strokes*.

³⁹ See *Nephrol Dial Transplant*. 2010 Jan;25(1):32-4. Epub 2009 Sep 15.

⁴⁰ See *J Clin Invest*. 2009 Jun;119(6):1616-25. Epub 2009 May 18.

⁴¹ See *Respir Med*. 2012 Mar;106(3):361-6. Epub 2011 Nov 29.

⁴² See *Biochem Biophys Res Commun*. 2004 Apr 23;317(1):108-13.

⁴³ See *Surg Today*. 2014 Mar;44(3):405-20. Epub 2013 May 9.

⁴⁴ See *J Am Coll Surg*. 2004 Nov;199(5):762-72.

⁴⁵ See *Anticancer Res*. 1998 Jan-Feb;18(1A):145-52.

⁴⁶ See *Circulation*. 2006 Oct 17;114(16):1713-20. Epub 2006 Oct 2.

⁴⁷ See *Ann Thorac Surg*. 2008 Feb;85(2):562-70.7

⁴⁸ See *Front Physiol*. 2011 Jun 23;2:27.

⁴⁹ Source: American Heart Association, Heart Disease and Stroke Statistics, 2014 Update, Table 18.1.

⁵⁰ Source: American Heart Association, Heart Disease and Stroke Statistics, 2014 Update, Table 19.1.

Midkine makes for great diagnostics

- **Midkine makes for a great cancer diagnostic.** We noted above that serum midkine is elevated in many different types of cancer but what makes a midkine antibody a great cancer biomarker is evidence that it is elevated in the very early stages of cancer. Various studies have suggested that midkine antibodies could be much more specific for cancer diagnosis than other, better-known biomarkers.
 - In one early study, midkine was able to detect 45% of breast cancer at 'Stage 0', where the cancer is only located at the point where it started, whereas antibodies for three biomarkers couldn't detect any⁵¹;
 - In 2003 Ikematsu et. al. showed that midkine could be used to diagnose the correct stage of neuroblastoma severity⁵²;
 - In 2003 Shimada et. al. showed that midkine serum concentration greatly enhanced disease detection over conventional markers in diagnosis of esophageal cancer patients⁵³;
 - In 2003 Shimada et. al. showed that serum midkine could function as an effective prognostic marker for esophageal cancer⁵⁴; and
 - In 2009 Ibusuki et. al. showed that the same approach worked in breast cancer⁵⁵.
- **Midkine has diagnostic applications well beyond cancer.** When Cellmid acquired Cell Signal in 2008 the company had developed diagnostics for early detection of cancer as well as for diagnosis of Rheumatoid Arthritis, Alzheimer's disease⁵⁶ and Sjögren's syndrome.
- **Cellmid has developed a midkine ELISA** which was launched in November 2010 for use in research applications. This ELISA, which has an 8 pg/mL limit of detection, well within the range of healthy serum midkine levels that can run as high as 1,000 pg/mL⁵⁷, gained its CE Mark in 2011.
- **There have been three diagnostic licensing deals since 2009**, one of which is now generating royalties for Cellmid:
 - A diagnostic for early detection of lung cancer was licensed to Celera in October 2009 and Quest Diagnostics⁵⁸, which bought Celera in 2011 for US\$344m, is currently doing clinical validation work⁵⁹;
 - A bladder cancer diagnostic was licensed to Pacific Edge⁶⁰ in May 2010 and launched in the US in March 2013; and
 - Coming soon is a midkine early cancer diagnostic, licensed to Japan's Fujikara Kasei⁶¹.
- **Cellmid now knows what healthy serum midkine should be**, thanks to a two year study conducted by Japan's Kumamoto University called 'CK3000'. This study screened 574 healthy volunteers – as determined by various other biomarkers and extensive lifestyle data – between 2011 and 2013, and found that normal levels of the protein were under 1,000 pg/mL. For the 2.7% of screened subjects with concentrations above this level, the investigators were able to follow up six and found that four of the six had previously been hospitalised for cancer or inflammatory disorders. We expect this study, yet to be published, will contribute to more diagnostics being developed.
- **Cellmid's diagnostic work is relevant to the cancer therapeutic programme**, since a successful drug will, like Herceptin and other cancer drugs, need a companion diagnostic before a patient went on the drug.

Pacific Edge launched its bladder cancer diagnostic from Cellmid in mid-2013

⁵¹ See Cellmid's 9 May 2008 presentation, slide 19. The biomarkers were CA15-3, BCA225 and CEA.

⁵² Cancer Res. 2001 Dec 1;61(23):8486-91.

⁵³ See Oncol Rep. 2003 Mar-Apr;10(2):411-4. The markers were p53 antibodies, CEA, SCC and CYFRA.

⁵⁴ See Cancer Sci. 2003 Jul;94(7):628-32.

⁵⁵ See Cancer Sci. 2009 Sep;100(9):1735-9. Epub 2009 Jun 1. The markers were CA15-3, CEA and NCCST-439.

⁵⁶ Yasuhara et. al. showed in 1993 that midkine is present in senile plaques of Alzheimer's Disease. See Biochem Biophys Res Commun. 1993 Apr 15;192(1):246-51.

⁵⁷ Cellmid has reported that the inter-assay CV of its ELISA is less than 25% and that the test was accurate with a recovery range of between 75% and 125%. Moreover there was no cross-reactivity to pleiotrophin or other serum components.

⁵⁸ Madison, NJ, NYSE: DGX, www.questdiagnostics.com.

⁵⁹ For data on the sensitivity and specificity of the test see Slides 30 and 31 of Cellmid's 30 September 2011 presentation.

⁶⁰ Dunedin, New Zealand, NZX: PEB, www.pacificedge.co.nz.

⁶¹ See www.fkkasei.co.jp.

Cellmid is in the hair regrowth business

- **Cellmid started selling hair regrowth products in 2010.** In the course of doing business in Japan, Cellmid was introduced in 2010 to a company called Advangen, which had developed various hair regrowth product based on FGF-5, a protein expressed by macrophage-like cells in the scalp that transitions hair follicles from growth to rest phase. Cellmid licensed the rights to Advangen's products for Australia and New Zealand and started selling them in December 2010. Two years later, in May 2013, Cellmid acquired the global rights to the products for \$1.2m cash and 55m Cellmid shares.
- **There is real science behind the products.** Antagonising FGF-5 is well known to promote hair growth⁶² and, since FGF-5 has no other known functions, it's reasonable to say that FGF-5 inhibitors are safe to use. Advangen's scientists had found that root extracts from two plants (*Sanguisorba officinalis* and *Eriobotrya japonica*) had anti-FGF-5 activity, and from these actives they had created three products – 'Jo-Ju Shampoo', 'Jo-Ju Scalp Lotion' and 'Lexilis Scalp Lotion'. A paper on the *S. officinalis* extracts is available at the Advangen web site⁶³.
- **évolis is a Cellmid-created brand.** Initially Cellmid took the Advangen intellectual property and prepared its own FGF-5-based hair regrowth product which it branded évolis. The product gained a TGA listing and launched commercially in 2012.
- **The data for évolis is good,** with Cellmid's own clinical study showing a 21% increase in the rate of hair growth and a 35% reduction in hair loss. 74% of users found the product beneficial. There are multiple channel partners for the product, including an online sales presence⁶⁴.
- **There is big theoretical demand for hair regrowth products like évolis.** Androgenic alopecia – the technical name for common hair loss – affects both sexes⁶⁵. While accurate numbers are hard to come by, we estimate around 30% of women and 60% of men are affected⁶⁶, which would mean around 100 million people in the US – 30 million women and 70 million men. This gigantic market has created two significant products in the last 25 years:
 - Propecia⁶⁷, an orally available a 5-alpha reductase inhibitor⁶⁸ from Merck & Co., gained FDA approval in 1992 as a treatment for benign prostatic hyperplasia⁶⁹, with an androgenic alopecia indication added five years later. Propecia lost US market exclusivity in January 2013. In 2012, its last full year of exclusivity, it was a US\$242m product. Propecia has side effects that have deterred a lot of potential users⁷⁰.
 - Rogaine, available as a foam from J&J⁷¹, lengthens the anagen (ie growth phase) of hair follicles. The drug originates from an old Upjohn blood pressure drug called Loniten, generic name minoxidil, which gained FDA approval in 1976. Noticing the effect on hair regrowth, Upjohn obtained an alopecia indication as Rogaine in 1988 and approval to sell over-the-counter in 1996. The product came into J&J's stable when Pfizer, Upjohn's eventual owner, sold its consumer products unit in 2006. It is, however, not a big seller – only US\$31m in US sales in 2006⁷² due to the fact that only around 20-25% of users see significant regrowth of the hair they have lost.
- **Cellmid is taking its hair regrowth business global with distributors being sought in key markets.** There was already Japanese distribution at the time of the Advangen acquisition in 2013. Cellmid now wants to sell worldwide. In January 2014 the company secured Chinese distribution via Huana Likang, a fast-growing direct marketing company with primary channels through television shopping networks and web-based sales. We expect other distribution agreements will follow over the next few years.

évolis is good for a 21% increase in the rate of hair growth

⁶² See Cell. 1994 Sep 23;78(6):1017-25.

⁶³ See www.advangen.com.au/scientific-publications.

⁶⁴ See www.evolisproducts.com.au.

⁶⁵ In spite of the name – 'andros' being the Greek word for 'men'. Specialists in the field often separate the condition into 'male pattern hair loss' and 'female pattern hair loss'.

⁶⁶ Estimated using data from J Investig Dermatol Symp Proc. 2005 Dec;10(3):184-9..

⁶⁷ Generic name finasteride, see www.propecia.com.

⁶⁸ 5-alpha reductase converts testosterone to 5 alpha-dihydrotestosterone (DHT). That hormone binds to receptors in scalp follicles and shrinks them.

⁶⁹ That is, enlargement of the prostate. BPH is androgen dependent, that is, driven by testosterone, and dihydrotestosterone is necessary for the hyperplasia to occur.

⁷⁰ Low libido, erectile dysfunction, decreased arousal and problems with orgasm – and this goes on at least two and a half years after you stop taking the drug. See J Sex Med. 2011 Jun;8(6):1747-53. Epub 2011 Mar 18.

⁷¹ See www.rogain.com.

⁷² See *Rogaine Seeks Place in the Morning Routine* by Andrew Adam Newman, New York Times, 24/1/2008

Valuing Cellmid – How we get 7 cents per share

- We valued Cellmid using a probability-weighted DCF approach.
- Our WACC was 14.1% (High risk)⁷³.
- We modelled payoffs for an anti-midkine cancer antibody, the cancer diagnostics and the suite of hair regrowth products.
- We model around 14 years of commercial exclusivity for the products followed by a negative 3-5% pa terminal growth rate. When we talk about 'Peak sales' we mean sales at year 14.

Risk weightings

- For the cancer antibody we used a 19% risk weighting for base case and 38% for optimistic case, to reflect the fact that the upcoming Phase I is in fact a Phase I/II with an easy lead-in to a full Phase II of the current study shows solid interim data in terms of response rates.
- For the cancer diagnostics and the consumer products we used no risk weightings. For the diagnostics, this is reasonable since Cellmid now knows what constitutes 'normal' serum midkine levels and there are multiple studies showing the effectiveness of a midkine diagnostic in cancer.

Commercial outcomes

- We assume that the cancer antibody licenses in 2015-2016, for US\$10-20m upfront, US\$100-150m milestones and 10-14% royalties. We assume that the products launch by 2018-2019 and model peak sales of US\$1.7-\$2.2bn.
- We assume that the diagnostics can gain a further US\$10-20m in upfronts and milestones by existing and future licensees. We model peak sales for all diagnostics of \$170-\$290m, with royalties ranging from 5% to 10%.
- For the haircare products, we assume continued self-distribution with sales peaking at \$13m-36m. We assume gross margins of between 50% and 70% is achievable over time.

Further capital

- We assume that the company raises \$3m at \$0.02 per share in order to complete the early clinical work on midkine in cancer.

How Cellmid can re-rate to our target price

- We see a number of potential re-rating events coming up over the next twelve months, including;
 - A pre-IND meeting with the FDA on the anti-midkine cancer programme;
 - Commencement of the Phase I/II;
 - First revenues from Pacific Edge related to the bladder cancer diagnostic;
 - New distribution agreements for évolis;
 - Launch of the lung cancer diagnostic by Quest.

⁷³ For a relevant discount rate, we use WACCs of between ~12% and ~16% depending on the risk for Life Science companies. This is derived from a RFR of 3.7%; a MRP of 7.5%-11.5% (7.5% for 'medium risk' companies, 9.5% for 'high risk' companies like Cellmid and 11.5% for 'speculative' companies); and an ungeared beta of 1.1. We regard Life Science companies with existing businesses, or who have enough capital to reach the market with their products, as 'Medium' risk. Companies that have small revenue streams from marketed products but that are still potentially in need of capital are 'High' risk. Everything else is 'Speculative'.

Leadership

- **CEO Maria Halasz**, who has been CEO of Cellmid since April 2007, brought to the company decades of experience advising Life Sciences investors, including some time as a venture partner at the Emerging Technology Fund of venture capital firm, Allen & Buckeridge. Ms Halasz sourced the midkine projects for Cellmid in 2008 as well as the hair care businesses and has moved these ventures forward to the point where a midkine programme is about to go clinical. We like Ms Halasz's focus on early stage revenue opportunities for midkine as well as hair care, which has been executed without neglecting the medium and long term opportunities from midkine.
- **Darren Jones**, Head of Product Development, brings strong knowledge of antibodies, built through years of benchtop research in cellular immunology as well as companies such as Immune System Therapeutics⁷⁴.
- **Koichiro Koike**, General Manager, Japan, brings valuable contacts in Japan which has helped to facilitate the acquisition of the midkine programmes by Cellmid.
- **Emma Chen**, VP Business Development, brings strong smarts in hair care from her previous role as CEO of Ashley & Martin, an Australian chain of hair loss treatment clinics.
- **The Cellmid board**, which includes Maria Halasz, has the skills required to build a large biotech company. Chairman Dr David King brings corporate skills built over many years in the Australian resources sector. Graeme Kaufman has been involved with a number of successful Life Sciences companies in Australia including CSL⁷⁵ and Mesoblast⁷⁶. And Martin Rogers was instrumental in rescuing the cancer immunotherapy company Prima Biomed⁷⁷ from oblivion in 2007 and taking it to Phase III by 2012.

Maria Halasz has brought in early stage revenue opportunities without neglecting the medium and longer term horizons

The risks

- We see four major risks related to Cellmid:
 - **Revenue risk.** There is the risk that sales of évolis and revenue from the midkine diagnostics in the early years will be perceived as low, leading to general disappointment with Cellmid as a stock;
 - **Development risk.** There is the risk that the cancer and inflammation programmes of Cellmid take longer than expected to make it into the clinic;
 - **Clinical risk.** There is the risk that the anti-midkine antibody fails to register responses in the first Phase I/II study in cancer; and
 - **Funding risk.** Even though Cellmid has some early revenue streams, there will likely be further capital required if the full potential of the midkine programmes are to be realised.

Major shareholders

- Currently there are no substantial shareholders in Cellmid.

⁷⁴ Sydney, Australia, privately held, www.istl.com.au. Immune System Therapeutics is working on a multiple myeloma antibody.

⁷⁵ Now the world's 27th largest pharma company – source: Pharmaceutical Executive.

⁷⁶ Mesoblast (Melbourne, Australia, ASX: MSB, www.mesoblast.com) is the world's leader in stem cell drug development.

⁷⁷ Redwood City, Ca., Nasdaq: PMBD, www.primabiomed.com.au.

Appendix I – A Cellmid glossary

Acute Myocardial Infarction (AMI) – The medical term for a heart attack, that is, a blockage of blood supply to the heart muscle (the myocardium).

Advangen – A Japanese company that had developed hair regrowth products which Cellmid is now commercialising.

Antibody – Immune system proteins that can bind to an antigen and help to neutralise the potentially harmful effects of the cells carrying the antigen.

Antisense – Methods for blocking the message – the ‘sense’- of the DNA behind the creation of a protein.

Alopecia – Complete or partial hair loss.

Angiogenesis – The process underlying the formation of new blood vessels, including the blood vessels which feed tumours.

Antigen – The ‘bad guy’ substance that stimulates the immune system to respond to the perceived threat. It is the protein to which antibodies bind.

Apoptosis – ‘Programmed’ cell death, that is, cell death that is naturally-occurring. Cancer cells tend to avoid apoptosis.

Aptamer – A nucleic acid molecule that binds to a specific target molecule.

Atherosclerosis – The clogging or hardening of blood vessels caused by plaques of fatty deposits, usually cholesterol.

Autoimmune disease – Disease in which the immune system is attacking ‘self’ antigens rather than ‘non-self antigens’. Rheumatoid Arthritis is an autoimmune disease.

Big Pharma – A collective term referring to the world’s largest pharmaceutical companies such as Eli Lilly, J&J, Merck & Co., Novartis and Pfizer.

Biomarker – A natural substance used as an indicator of a biological state, especially to detect the presence or severity of disease.

Blockbuster – A pharmaceutical drug with more than US\$1bn in annual sales.

Cardiac remodelling – Changes in cardiac tissue as a result of heart failure.

COPD – Short for Chronic Obstructive Pulmonary Disease, COPD is an umbrella term for a number of progressive, long-term lung conditions characterised by shortness of breath due to reduced airflow through the airways.

Diabetic nephropathy – Kidney damage resulting from diabetes, which can often lead to kidney failure.

Dose escalation – A situation in a drug trial where an increasing dose is administered in order to find an optimal dose.

ELISA – Short for Enzyme-Linked ImmunoSorbent Assay, a test method for antigens in blood that involves the detection of a linked enzyme. ELISAs represent a way of screening many samples at once, through the use of trays containing multiple sample wells.

évolis – Cellmid’s hair regrowth product that works through inhibition of FGF-5.

FDA – The Food and Drug Administration, the American government body which regulates the pharmaceutical industry and from whom approval must be received before a drug can be marketed in the US.

FGF-5 – A growth factor that regulates hair growth. Cellmid’s hair regrowth products work by inhibition of FGF-5.

Glomerular sclerosis – A condition in which the glomeruli – the network of blood-filtering capillaries in the kidney – become scarred and gradually lose their function.

Haemopoietic stem cells – Stem cells that help build the body’s blood supply.

Heart failure – A condition where the heart is unable to pump adequate amounts of blood around the body. Heart failure often follows on from an Acute Myocardial Infarction.

Heparin – A compound occurring in the liver and other tissues which inhibits blood coagulation. Natural and synthetic heparin are used as anti-clotting drugs.

Infarct – A localised area of dead tissue resulting from failure of blood supply.

In vitro – Latin for ‘in glass’, referring to data obtained through testing in a test tube.

Ischemia – Lack of adequate blood flow to support the normal functioning of a tissue.

Knockout mice – Mice that have been bred to lack a particular gene, so that the effect of that loss can be studied.

Macrophages – White blood cells involved in the immune system’s response to infection. Macrophages are not found in the bloodstream but at locations where body organs interface with the environment or the bloodstream.

Midkine (mk) – A small heparin-binding growth factor protein that is important in embryonic development and, while not detectable in healthy adults, is highly expressed in cancer and autoimmune disorders.

Monoclonal antibodies – Antibodies cloned from a particular cell-making antibody that is highly specific for a particular antigen. Monoclonal antibodies are increasingly used as drugs.

Neuroblastoma – A cancer of the neuroblast nerve cell precursors, occurring most often in infants and young children. Neuroblastoma is rare, with only ~700 new cases in the US each year.

Neutrophil – A white blood cell vital for immune system function. Neutrophils work by ingesting foreign cells.

Non-small-cell lung cancer (NSCLC) – One of two main types of lung cancer, the other being small-cell lung carcinoma. Non-small cell lung cancer is easier to surgically remove.

Oligonucleotides – Short strings of nucleotides, that is, DNA or RNA ‘letters’ from the genetic alphabet.

Oncogenic – Capable of causing cancer.

Open label – A clinical trial in which both patients and doctors know what treatment is being administered.

PTCA – Short for Percutaneous Transluminal Coronary Angioplasty, a surgical procedure to repair a damaged blood vessel or unblock a coronary artery. In PTCA a balloon is inserted via a catheter into the vessel and then expanded.

pg/mL – Picograms per millilitre, a measurement of the serum concentration of rarely-occurring proteins. A picogram is a trillionth of a gram.

Phase – A stage of the clinical trialling process for a drug candidate. Phase I tests for safety. Phase II tests for efficacy in a small sample. Phase III tests for efficacy in a large sample.

Regulatory T cells – T cells which turn down an immune response.

Reperfusion – The return of blood supply to tissue after a period of ischemia.

Restenosis – A re-narrowing or blockage of an artery at a site where angioplasty was previously done. An angioplasty is a procedure to open clogged arteries, performed after a heart attack. Restenosis often follows administration of a stent.

Sepsis – Serious and potentially life-threatening inflammation caused by severe infection.

Serum – Blood plasma from which the clotting proteins have been removed. Plasma is the clear fraction of the blood. The serum concentration of a protein relative to its normal level can be indicative of disease.

Sjögren’s syndrome – An autoimmune disorder in which the white blood cells attack the moisture-producing glands, causing decreased production of saliva and tears. Sjögren’s syndrome may affect 3-4% of the adult population⁷⁸.

Trispecific – An antibody drug that can hit three different targets.

Wild-type – The natural version of a particular gene, protein, or strain.

Xenograft – An animal model of cancer in which a human tumour is grafted onto a mouse without a functioning immune system, so that the tumour will stay in place.

⁷⁸ See Br J Rheumatol. 1998 Oct;37(10):1069-76.

Appendix II – Key patents

- **Novel use of mk family as hematopoietic factor**, WO/1998/001151, Exp. Jan-2017⁷⁹. This patent application covers the use of midkine as a growth factor in the expansion of hematopoietic stem cells for use in bone marrow transplant.
- **Drugs containing as the active ingredient midkine or inhibitors thereof**, WO/1999/003493, Exp. Jan-2018⁸⁰. This patent application covers the therapeutic uses that can be made of midkine as a promoter of neutrophilic inflammation.
- **Preventives or remedies for ischemic diseases**, WO/1999/016463, Exp. Jan-2018⁸¹. This patent application covers the use of midkine protein in treating heart attack and stroke.
- **Mass secretion/expression system of true mk family protein**, WO/2000/009718, Exp. Jan-2019⁸². This patent application covers a yeast-based expression system for producing midkine protein.
- **Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA**, WO/2000/010608, Exp. Jan-2019⁸³. This patent application covers midkine inhibitors used to prevent restenosis following heart bypass surgery.
- **Early cancer tumour marker**, WO/2001/020333, Exp. Jan-2020⁸⁴. This patent application covers the use of midkine in cancer diagnostics.
- **Preventive for adhesion following abdominal surgery**, WO/2004/078210, Exp. Jan-2024⁸⁵. This patent application covers the use of midkine inhibitors in preventing surgical adhesions by blunting the associated inflammation.
- **Hair growth stimulant composition**, WO/2005/034894, Exp. Jan-2024⁸⁶. This patent application covers the use of FGF-5 inhibitors in promoting hair regrowth.
- **Composition for treating or preventing myocardial disorder or heart failure**, WO/2006/062087, Exp. Jan-2025⁸⁷. This patent application covers the use of midkine protein in treating heart attack and thereby preventing heart failure.
- **Pharmaceutical composition for vascular occlusive disease**, WO/2006/126600, Exp. Jan-2026⁸⁸. This patent application covers the use of midkine to treat various disease conditions in which blood vessels are in danger of closing.
- **Method for treatment or prevention of disease associated with functional disorder of regulatory T cell**, WO/2007/055378, Exp. Jan-2026⁸⁹. This patent application covers the use of midkine antagonists in treating Multiple Sclerosis.
- **Therapeutic agent for occlusive peripheral vascular disease, and use thereof**, WO/2008/047904, Exp. Jan-2027. This patent application covers the use of midkine in promoting the new blood vessel growth which would treat peripheral artery disease.
- **Antibody recognising C-domain of midkine**, WO/2008/059616, Exp. Jan-2027⁹⁰. This patent application covers antibodies to one of the two midkine domains.
- **Nitric oxide synthase activator**, WO/2008/129851, Exp. Jan-2028⁹¹. This patent application covers the use of midkine in vasodilation, that is, expansion of blood vessels through activation of nitric oxide synthase.
- **Method of treatment or prevention of hair loss or for the enhancement of hair growth**, WO/2011/103624, Exp. Jan-2031⁹². This patent application covers the use of midkine as a promoter of hair growth.

⁷⁹ This patent application has been granted in the US as Patents No. 6,383,480 (May 2002) and 6,939,669 (September 2005) and in Europe as EP 0 937 461 (July 2005).

⁸⁰ This patent application has been granted in the US as Patent No. 7,390,491 (June 2008) and in Europe as EP 0 998 941 (June 2006).

⁸¹ This patent application has been granted in Europe as EP 1 057 489 (January 2007).

⁸² This patent application has been granted in the US as Patent No. 6,867,037 (March 2005).

⁸³ This patent application has been granted in the US as Patent Nos. 7,309,695 (December 2007) and 7,820,160 (October 2010) and in Europe as EP 1 108 436 (August 2009).

⁸⁴ This patent application has been granted in the US as Patent No. 7,090,983 (August 2008) and in Europe as EP 1 215 500 (July 2008).

⁸⁵ This patent application has been granted in the US as Patent No. 8,221,758 (July 2012).

⁸⁶ This patent application was made by Advangen.

⁸⁷ This patent application has been granted in Europe as EP 1 832 296 (August 2009).

⁸⁸ This patent application has been granted in Europe as EP 1 900 380 (March 2013).

⁸⁹ This patent application has been granted in the US as Patent No. 8,128,934 (March 2012).

⁹⁰ This patent application has been granted in Europe as EP 2 088 159 (March 2014).

⁹¹ This patent application has been granted in the US as Patent No. 8,288,343 (October 2012).

⁹² This patent application was made by Advangen.

- **Antibody recognising N-domain of midkine**, WO/2012/122590, Exp. Jan-2032. This patent application covers antibodies to the other midkine domains, WO/2008/059616 above having covered the C-domain.
- **Biochemical evaluation method**, WO/2013/105417, Exp. Jan-33⁹³. This patent application covers a method of detecting whether or not a growth factor is having the desired effect on cell growth. It involves culturing dermal papilla cells in the presence of the growth factor and measuring the level of alkaline phosphatase activity.

Appendix III – Comparable companies

FIG.1: CELLMID COMPARABLES

Name	Location	Code	Market cap (USDm)	Web site
Sorrento Therapeutics	San Diego, Ca.	Nasdaq: SRNE	141.6	www.sorrentotherapeutics.com
Epigenomics	Berlin, Germany	Xetra: ECX	118.5	www.epigenomics.com
Vermillion	Austin, Tx.	Nasdaq: VRML	98.5	www.vermillion.com
Stem Cell Therapeutics	Calgary, Ab.	CVE: SSS	70.0	www.stemcellthera.com
Lpath	San Diego, Ca.	Nasdaq: LPTN	63.4	www.lpath.com
LipoScience	Raleigh, NC	Nasdaq: LPDX	48.8	www.liposcience.com
Bioinvent	Lund, Sweden	Nasdaq OMX Stockholm:	48.8	www.bioinvent.com
Response Genetics	Los Angeles, Ca.	Nasdaq: RGDX	38.7	www.responsegenetics.com
Immune Pharmaceuticals	Herzliya, Israel	OTCQX: IMNP	38.1	www.immunepharmaeaceuticals.com

Source: Company data

- **Bioinvent.** This cancer antibody drug developer, built on an antibody screening tool called F.I.R.S.T, is getting ready to go to the clinic with BI-505, an antibody specific for the adhesion protein ICAM-1, overexpressed in several tumours but not widely expressed in normal tissue. The initial indication will be in multiple myeloma.
- **Epigenomics.** This company, built on methods to detect DNA methylation, develops cancer-specific molecular diagnostics. The company's lead product, Epi proColon, a blood test for the early detection of colorectal cancer, is currently marketed in Europe.
- **Immune Pharmaceuticals.** This company's lead product is bertilimumab, a Phase II antibody for ulcerative colitis and Crohn's Disease. The company is also working on antibody nanoparticle conjugates for the targeted delivery of chemotherapeutics as well as a couple of small molecules in cancer and neuropathic pain.
- **LipoScience.** This company's technology enables lipoproteins and other and small molecule metabolites relevant to disease to be identified from a blood sample using nuclear magnetic resonance. The company's first FDA-approved product is the NMR LipoProfile for quantifying particles of LDL, that is, 'bad' cholesterol.
- **Lpath.** This company develops antibodies that target bioactive lipids. The company's lead candidate is sonopizumab, which targets S1P and is in Phase II in wet AMD. An S1P antibody is useful in various disease conditions including cancer, MS and ulcerative colitis. The wet AMD indication was optioned to Pfizer in December 2010 for US\$14m upfront. Pfizer has since been seeking new assignees for this option.
- **Response Genetics.** This company develops cancer molecular diagnostics using technology to extract genetic information from tumour samples. The company currently generates revenue from analytical pharmacogenomic testing services of clinical trial specimens. The company's ResponseDX Biomarker tests are used to test for lung, colon, gastric, melanoma, breast and thyroid cancers.
- **Sorrento Therapeutics.** This cancer drug developer has Cynviloq, a nanoparticle formulation of paclitaxel, as its lead compound in late stage clinicals. Resiniferatoxin, a non-opiate pain therapeutic for cancer pain, is in mid-stage clinical development. Various antibody drugs are pre-clinical.

⁹³ This patent application was made by Advangen.

- **Stem Cell Therapeutics.** This company is focused on cancer stem cell therapies. Its most promising cancer products, both preclinical, are an antibody-like fusion protein to CD47, and an antibody to CD200. The CD47 product is targeting cancer stem cells in Acute Myeloid Leukaemia. The CD200 product hits a molecule overexpressed by many tumours.
- **Vermillion.** This company develops diagnostics specific to gynaecologic cancers – cervical, ovarian, uterine and vaginal/ vulvar – as well as women's health. The company's main product is its OVA1 test, which measures five proteins relevant in ovarian cancer.

This document has been prepared and issued by:

Baillieu Holst Ltd

ABN 74 006 519 393

Australian Financial Service Licence No. 245421

Participant of ASX Group

Participant of NSX Ltd

Analysts' stock ratings are defined as follows:

Buy: The stock's total return is expected to increase by at least 10-15 percent from the current share price over the next 12 months.

Hold: The stock's total return is expected to trade within a range of $\pm 10-15$ percent from the current share price over the next 12 months.

Sell: The stock's total return is expected to decrease by at least 10-15 percent from the current share price over the next 12 months.

Disclosure of potential interest and disclaimer:

Baillieu Holst Ltd (Baillieu Holst) and/or its associates may receive commissions, calculated at normal client rates, from transactions involving securities of the companies mentioned herein and may hold interests in securities of the companies mentioned herein from time to time. Your adviser will earn a commission of up to 50% of any brokerage resulting from any transactions you may undertake as a result of this advice.

When we provide advice to you, it is based on the information you have provided to us about your personal circumstances, financial objectives and needs. If you wish to rely on our advice, it is important that you inform us of any changes to your personal investment needs, objectives and financial circumstances.

If you do not provide us with the relevant information (including updated information) regarding your investment needs, objectives and financial circumstances, our advice may be based on inaccurate information, and you will need to consider whether the advice is suitable to you given your personal investment needs, objectives and financial circumstances. Please do not hesitate to contact our offices if you need to update your information held with us. Please be assured that we keep your information strictly confidential.

No representation, warranty or undertaking is given or made in relation to the accuracy of information contained in this advice, such advice being based solely on public information which has not been verified by Baillieu Holst Ltd.

Save for any statutory liability that cannot be excluded, Baillieu Holst Ltd and its employees and agents shall not be liable (whether in negligence or otherwise) for any error or inaccuracy in, or omission from, this advice or any resulting loss suffered by the recipient or any other person.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments.

Baillieu Holst Ltd assumes no obligation to update this advice or correct any inaccuracy which may become apparent after it is given.

Baillieu Holst Ltd

ABN 74 006 519 393

Australian Financial Service Licence No. 245421

Participant of ASX Group

Participant of NSX Ltd

www.baillieuholst.com.au

Melbourne (Head Office)

Address Level 26, 360 Collins Street

Melbourne, VIC 3000 Australia

Postal PO Box 48, Collins Street West

Melbourne, VIC 8007 Australia

Phone +61 3 9602 9222

Facsimile +61 3 9602 2350

Email melbourne@baillieuholst.com.au

Bendigo Office

Address Cnr Bridge & Baxter Streets

Bendigo, VIC 3550 Australia

Postal PO Box 40

North Bendigo, VIC 3550 Australia

Phone +61 3 5443 7966

Facsimile +61 3 5442 4728

Email bendigo@baillieuholst.com.au

Geelong Office

Address 16 Aberdeen Street

Geelong West Vic 3218

Postal PO Box 364

Geelong Vic 3220 Australia

Phone +61 3 5229 4637

Facsimile +61 3 4229 4142

Email geelong@baillieuholst.com.au

Newcastle Office

Address Level 1, 120 Darby Street

Cooks Hill, NSW 2300 Australia

Postal PO Box 111

The Junction, NSW 2291 Australia

Phone +61 2 4925 2330

Facsimile +61 2 4929 1954

Email newcastle@baillieuholst.com.au

Perth Office

Address Level 10, 191 St Georges Terrace

Perth WA 6000 Australia

Postal PO Box 7662, Cloisters Square

Perth, WA 6850 Australia

Phone +61 8 6141 9450

Facsimile +61 8 6141 9499

Email perth@baillieuholst.com.au

Sydney Office

Address Level 18, 1 Alfred Street

Sydney, NSW 2000 Australia

Postal PO Box R1797

Royal Exchange, NSW 1225 Australia

Phone +61 2 9250 8900

Facsimile +61 2 9247 4092

Email sydney@baillieuholst.com.au